CALT Stock Overview
A commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CALT from our risk checks.
Calliditas Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr21.50 |
| 52 Week High | kr29.30 |
| 52 Week Low | kr15.25 |
| Beta | 1.4 |
| 1 Month Change | 18.90% |
| 3 Month Change | 4.88% |
| 1 Year Change | 16.78% |
| 3 Year Change | -28.90% |
| 5 Year Change | n/a |
| Change since IPO | 10.83% |
Recent News & Updates
Recent updates
Calliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64M
Aug 18Calliditas Therapeutics wins European approval for Kinpeygo for IgA nephropathy
Jul 15Calliditas submits nefecon marketing authorisation application to the EMA
May 28Calliditas shares rise 10% as FDA grants priority review for Nefecon
Apr 28Calliditas Therapeutics reports Q3 results
Nov 12Shareholder Returns
| CALT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.9% | 1.9% | 1.2% |
| 1Y | 16.8% | 16.7% | 27.7% |
Return vs Industry: CALT matched the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: CALT underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| CALT volatility | |
|---|---|
| CALT Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CALT has not had significant price volatility in the past 3 months.
Volatility Over Time: CALT's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 217 | Renee Aguiar-Lucander | www.calliditas.se |
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company’s lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome.
Calliditas Therapeutics AB (publ) Fundamentals Summary
| CALT fundamental statistics | |
|---|---|
| Market cap | US$582.32m |
| Earnings (TTM) | -US$43.60m |
| Revenue (TTM) | US$112.88m |
5.2x
P/S Ratio-13.4x
P/E RatioIs CALT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CALT income statement (TTM) | |
|---|---|
| Revenue | kr1.21b |
| Cost of Revenue | kr60.46m |
| Gross Profit | kr1.15b |
| Other Expenses | kr1.61b |
| Earnings | -kr466.18m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 23, 2024
| Earnings per share (EPS) | -8.69 |
| Gross Margin | 94.99% |
| Net Profit Margin | -38.63% |
| Debt/Equity Ratio | 280.6% |
How did CALT perform over the long term?
See historical performance and comparison